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Abstract
The present report highlights the most important papers appearing
in Critical Care and other major journals about severe sepsis, the
systemic inflammatory response and multiorgan dysfunction over
the past year. A number of these clinical and laboratory studies will
have a considerable impact on the sepsis research agenda for
years to come. The steroid controversy, the debate over tight gly-
cemic control, the colloid versus crystalloid issue, the value of
selective decontamination of the digestive tract, the enlarging role
of biomarkers, the value of genomics and rapid diagnostic
techniques have all been prominently featured in recent publica-
tions. Basic research into novel predictive assays, genetic poly-
morphisms, and new molecular methods to risk-stratify and to
determine treatment options for sepsis have occupied much of the
Critical Care publications relating to sepsis pathophysiology in
2008. We will attempt to briefly summarize what we consider to be
the most significant contributions to the sepsis literature over the
last year, and their likely ramifications in the future, for critical care
clinicians, clinical investigators and basic researchers alike.
Introduction
2008 was a significant year in Critical Care, with a number of
landmark papers being published in sepsis research in this
journal and in other publications. These studies cross the
spectrum from some highly promising results to some very
disappointing clinical and laboratory findings reported in the
literature over the past year. The year started off on a positive
note with the publication of the much anticipated and fre-
quently quoted 2008 sepsis management guidelines from the
Surviving Sepsis Campaign [1]. Encouraging evidence that
the adoption of the Surviving Sepsis Campaign Guidelines
can achieve measurable improvements in patient outcome
has already appeared [2,3]. Despite the intrinsic hetero-
geneity that typifies sepsis [4], standardized treatment
regimens can improve outcome. Improvements in the process
of care (for example, immediate resuscitation with intravenous
fluids with preset physiologic goals, urgent administration of
antimicrobial therapy, rapid identification and source control),
and a variety of other evidence-based supportive measures,
can improve survival in critically ill septic patients [1].
Two highly disappointing results were reported from large,
randomized, clinical trials in 2008. The first major dis-
appointment was the Corticus trial [5], which was expected
to be a confirmatory trial from the Annane low-dose steroid
study [6]. Treatment with relatively low doses of hydro-
cortisone (50 mg intravenously every 6 hours) followed by a
tapering dose was compared with a placebo group in a
multicenter randomized trial. The Corticus trial showed no
overall survival benefit from the use of this seemingly logical,
inexpensive treatment strategy for the relative adrenal
insufficiency often accompanying septic shock. The study did
find a significantly more rapid reversal in the duration of
septic shock in the low-dose steroid group. This potential
benefit of steroid-related shock reversal was accompanied by
an increased incidence of secondary infections and
secondary septic shock compared with the placebo group.
The adrenocorticotrophic hormone stimulation test was used
to differentiate responders from nonresponders with relative
adrenal insufficiency. This finding did not distinguish patients
more likely to respond to corticosteroids [5].
The German Sepsis Society clinical research group pub-
lished two simultaneous clinical trials in which tight glycemic
control was compared with standard glucose control, and
pentastarch colloid solution was compared with crystalloid
therapy for fluid resuscitation in severely septic patients (the
VISEP trial) [7]. Again, the results were highly disappointing
with no improvement in overall outcome of tight glycemic
control with excess incidence of hypoglycemic events. These
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negative results were recently confirmed by a large pros-
pective clinical trial of tight glycemic control versus
conventional glycemic control from Australia, New Zealand
and Canada (the NICE-SUGAR Study) [8]. This study, which
included over 6,000 patients, actually revealed a significantly
worse outcome for those patients randomized to tight gly-
cemic control over conventional glucose management. Tight
glycemic control carries a real risk of hypoglycemic episodes
and is of uncertain efficacy in a general intensive care unit
(ICU) population. Likewise, the colloid treatment strategy with
pentastarch in the VISEP trial demonstrated a dose-
dependent worsening in renal function compared with
standard crystalloid resuscitation fluids, and its use should be
discouraged in the future. Whether these findings can be
extended to other colloids such as gelatin and albumin
remains to be demonstrated. The results are not likely to end
the continuing controversy regarding colloids versus
crystalloids in sepsis therapy.
The year ended with an important publication addressing a
decade-long argument about the value of selective decon-
tamination of the digestive tract versus standard care in a
general ICU population. deSmet and colleagues reported a
modest survival advantage in the selective decontamination
of the digestive tract population (including a systemic chemo-
prophylaxis group and an oral chemoprophylaxis only group)
versus conventional therapy in a 5,939-patient trial [9]. The
28-day mortality rate was 27.5% for the control group, 26.9%
for the oral selective decontamination of the digestive tract
group, and 26.6% for the systemic selective decontamination
of the digestive tract group (P <0.05). The oral therapy might
be easier to bring into standard ICU care as this strategy
could limit the concerns about selecting for multidrug-
resistant bacteria and even Clostridium difficile infection with
widespread adoption of systemic chemoprophylaxis as a
general strategy in ICU patients.
Major research findings in sepsis and
systemic inflammatory states reported in
Critical Care during 2008
Many important sepsis research papers appeared in Critical
Care during the past year. Many of these studies are
association studies where various novel biomarkers, enzymes
and mediators were compared with the development of
severe sepsis, organ dysfunction and adverse clinical out-
comes [10-19]. These new research findings are summarized
in Table 1. Some of the more notable findings from basic
science to clinical research studies are highlighted in the
following paragraphs.
Biomarkers for the diagnosis and risk stratification of
multiorgan failure and sepsis
Soluble triggering receptor on myeloid cells 1
Soluble triggering receptor on myeloid cells 1 (sTREM-1) is a
member of the immunoglobulin superfamily that is up-
regulated on the surface of neutrophils, monocytes and
macrophages in the presence of extracellular bacteria and
fungi. Early studies by Gibot and colleagues demonstrated a
diagnostic sensitivity of 98% and a specificity of 90% for
detecting pneumonia by the measurement of sTREM-1 from
mini-bronchoalveolar lavage (mini-BAL) fluids [20].
Huh and colleagues examined the diagnostic role of sTREM-1
in BAL fluid in 80 patients with bilateral lung infiltrates [10].
The authors compared BAL sTREM-1 with the clinical
pneumonia infection severity score and the BAL neutrophil
percentage in three patient groups: extracellular bacterial and
fungal infection; pneumonia due to atypical intracellular
bacteria, mycobacteria or viruses; and noninfectious ill-
nesses. The levels of sTREM-1 were statistically significantly
greater in the extracellular bacteria and fungal group
(521.2 ± 94.7 pg/ml) compared with the viral/mycobacterial/
atypical pathogen group (92.9 ± 20 pg/ml) and the non-
infected group (92.8 ± 10.7 pg/ml). At a cutoff level of
184 pg/ml, sTREM-1 had a sensitivity of 86% and 90%
specificity. While a clinical pneumonia infection severity score
of 6 or greater and a BAL neutrophil percentage of 60% were
statistically greater in the infected groups versus the non-
infected group, sTREM-1 had the highest area under the
receiver operating characteristic curve at 0.91 and was the
only remaining variable statistically significant on multiple
logistic regression analysis [10].
The findings in Huh and colleagues’ study are in agreement
with those of Richeldi and colleagues, where sTREM-1
differentiated community-acquired pneumonia from tubercu-
losis and interstitial lung disease [21]. Individual studies by
Horonenko and colleagues and by Anand and colleagues did
not show the same diagnostic accuracy with sTREM-1 as the
Huh and colleagues study [22,23] – both of these studies
demonstrated false positive s-TREM levels in the setting of
pulmonary hemorrhage. The allowance of patients with prior
antibiotic administration in Anand and colleagues’ study may
have contributed to the discordant results. Future studies of
sTREM-1 will need to be performed with a standardized
assay and procedure for the BAL collection, and must
examine the effect of antibiotic therapy on sTREM-1 levels.
Eosinopenia
A surprising simple measure to differentiate infection from
noninfectious inflammation by eosinophil counts has
resurfaced recently [11]. This is not a new idea but is
appealing in its simplicity and availability [24]. The mechanism
underlying eosinopenia is thought to be chemotactic factors,
which draw the eosinophils to the site of infection [25].
Abidi and colleagues examined the value of eosinopenia in
differentiating sepsis from noninfectious systemic inflam-
matory response syndrome in 198 medical ICU patients [11].
Patients without infection had a median eosinophil count of
109 cells/mm3 (interquartile range = 102 to 121), compared
with 13 cells/mm3 (interquartile range = 8 to 28) in those withinfection (P <0.001). An eosinophil cutoff value <50 cells/mm3
provided a sensitivity of 80%, a specificity of 91%, a
likelihood ratio of 9.12, and an area under the receiver
operating characteristic curve of 0.89. This was superior to
C-reactive protein at a cutoff value of 70. By way of
comparison, a meta-analysis by Tang and colleagues of the
ability of procalcitonin to diagnose sepsis in critically ill
patients with systemic inflammatory response syndrome
revealed an area under the receiver operating characteristic
curve of 0.78 [26]. Procalcitonin is the currently favored
assay for distinguishing severe infection from systemic
inflammation without infection, but it has its limitations [27].
The total eosinophil count as a biomarker in the diagnosis of
sepsis needs to be studied in a large, multicenter study.
Gelsolin
Gelsolin is a cytoplasmic and plasma protein that works as an
actin scavenger. Actin is released during tissue injury and has
been noted to be toxic [28]. Additionally, gelsolin has been
shown to inhibit inflammatory mediators released during sepsis
including endotoxin, lysophosphatidic acid, and platelet
activating factor [29]. Plasma gelsolin deficiencies have been
described in patients with a variety of severe inflammatory
states [30], and animal models of sepsis reveal a survival
advantage with gelsolin replacement therapy [31].
Wang and colleagues investigated the time course of plasma
gelsolin concentrations in 91 critically ill surgical patients
[12]. Patients with severe sepsis had significantly lower
gelsolin levels (20.6 ± 11.7 mg/l) than nonseptic critically ill
patients (52.3 ± 20.3 mg/l) and healthy control individuals
(126.8 ± 32.2 mg/l). Plasma gelsolin levels were inversely
correlated with disease severity, with the lowest levels
(17.1 ± 9.1 mg/l) occurring in patients with Acute Physiology
and Chronic Health Evaluation II scores >25. Baseline
gelsolin levels did not distinguish between survivors and
nonsurvivors from sepsis. These results are comparable with
a recent study by Lee and colleagues that gelsolin deficiency
is a marker of disease severity, but did not confirm its
prognostic ability [32]. The optimal assay for measuring
gelsolin and the cutoff value needs further evaluation.
Angiopoietin 1 and angiopoietin 2
Biomarkers of endothelial cell integrity are being studied as
prognostic markers in sepsis and multiorgan failure. Inflam-
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Table 1
Selected biomarker studies and disease association studies in Critical Care (2008)
Patient type or 
Molecule Reference Number studied animal model Main findings
sTREM Huh and  80 VAP patients sTREM in BAL fluid was highest in bacterial infection 
colleagues [10] patients, high in viral/mycobacterial pneumonia 
patients and low in noninfected patients
Eosinopenia Abidi and  198 Sepsis patients  Low eosinophil levels discriminate infection from
colleagues [11] noninfectious inflammation and are comparable with
PCT and CRP as predictors
Gelsolin Wang and  91 Surgical patients Gelsolin is an actin scavenger, and reduced levels of 
colleagues [12] gelsolin are associated with worsening sepsis
Kerbs von Lungren 6 Nathani and  42 ARDS and at-risk  Kerbs von Lungren 6 is an alveolar type 2 cell marker 
colleagues [13] patients associated with increased risk of ARDS 
Copeptin Seligman and  71 VAP patients Copeptin is a derivative of preproAVP and a strong 
colleagues [14] predictor of mortality in VAP
Protein disulfide  Zhou and  30 CLP or LPS-treated  PDI suppresses TNF gene expression in septic states; 
isomerase colleagues [15] rats  reduced PDI upregulates TNF 
Bim and Bid gene  Weber and  37 Septic patients Bim and Bid proapoptotic genes are strongly 
expression colleagues [16] upregulated in sepsis and lymphocyte depletion
Endothelin-1 Trachsel and  28 LPS-treated pigs Endothelin-1 levels correlate with pulmonary 
colleagues [17] hypertension and responsiveness to inhaled nitric 
oxide
Reactive oxygen  Martins and  41 Septic patients ROS are upregulated in myeloid cells and are 
species  colleagues [18] correlated with adverse outcome 
Akt and ERK1/2 Li and colleagues [19] 77 C57/BL6 mice Akt and ERK1/2 mediate in part pulmonary 
injury/fibrosis from high tidal volume ventilation
Akt, serine/threonine kinase B; ARDS, acute respiratory distress syndrome; AVP, arginine vasopressin; BAL, bronchoalveolar lavage; CLP, cecal
ligation and puncture; CRP, C-reactive protein; ERK1/2, extracellular signal regulated kinase 1/2b; LPS, lipopolysaccharide; PCT, procalcitonin;
PDI, protein disulfide isomerase; ROS, reactive oxygen species; sTREM, soluble triggering receptor expressed on myeloid cells; VAP, ventilator-
associated pneumonia.matory mediators released during the sepsis response can
disrupt endothelial cell integrity and cause microcirculatory
dysfunction that manifests itself as shock and acute
respiratory distress syndrome. Angiopoietin 1 and angio-
poietin 2 are ligands for the endothelial Tie-2 receptor that
protect and disrupt the endothelial barrier, respectively [33].
Kumpers and colleagues examined angiopoietin 1 and angio-
poietin 2 as predictors of mortality and for correlation with
disease severity and organ injury [34]. They studied 43
medical ICU patients with septic shock, severe sepsis, or
nonseptic critical illness and 29 healthy control individuals.
Both angiopoietin 1 and angiopoietin 2 levels were statis-
tically significantly higher in the critically ill population than in
controls, but only angiopoietin 2 was statistically significantly
higher in sepsis patients compared with the nonseptic
critically ill population. Angiopoietin 2 levels strongly
correlated with traditional markers of disease severity includ-
ing Acute Physiology and Chronic Health Evaluation II score,
Sequential Organ Failure Assessment score and lactate
levels. In a multivariate analysis, angiopoietin 2 was the only
independent predictor of death.
The accumulating literature on angiopoietin 2 suggests that it
may not only be a marker of disease severity in acute respira-
tory distress syndrome but it may also be a therapeutic target.
Parikh and colleagues demonstrated an inverse correlation
between angiopoietin 2 levels and oxygenation. Angiopoietin 2
applied to endothelial cell monolayers increased membrane
permeability [35]. A mouse model of endotoxic shock
showed a survival advantage with administration of angio-
poietin 1 [36]. We look forward to further investigation of the
Tie-2 receptor in acute respiratory distress syndrome.
Potential new therapies
High molecular weight hyaluronan
High molecular weight hyaluronan (HMW HA) is an important
component of the lung interstitium that helps to maintain the
structural integrity and compliance of the lung. Low molecular
weight hyaluronan (LMW HA) can be produced by degrada-
tion of HMW HA or by de novo synthesis. LMW HA but not
HMW HA is capable of eliciting an inflammatory response. A
transgenic mouse that overproduces HMW HA through the
hyaluronan synthase enzyme is protective in a bleomycin
model of acute lung injury [37].
The hypothesis that HMW HA could be a lung-protective
molecule was tested by Liu and colleagues in a sepsis-
induced lung injury model [38]. Rats were divided into four
groups: nonventilated rats; ventilated rats with lipopoly-
saccharide challenge; ventilated rats with lipopolysaccharide
challenge and pretreatment 18 hours prior to or treatment
1 hour after with HMW HA (1,600 kDa); and ventilated rats
with lipopolysaccharide challenge with LMW HA (35 kDa)
18 hours before challenge. Either LMW HA or HMW HA was
able to decrease neutrophil accumulation in the lung and to
decrease the concentration of TNF and macrophage-inflam-
matory protein 2 caused by lipopolysaccharide. Only HMW
HA pretreatment and post-treatment could block the
monocyte accumulation and decrease lung injury. While the
mechanism of protection is not clearly known, further studies
are warranted to determine the dose and size of HMW HA to
limit acute lung injury/acute respiratory distress syndrome.
Danaparoid
Anticoagulant molecules have recently been of great interest
as potential therapies for severe sepsis and septic shock.
Danaparoid is a low molecular weight heparanoid composed
of 83% heparan sulfate and 12% dermatan sulfate that
blocks the coagulation cascade by binding to antithrombin
and inhibiting factor Xa. Inhibiting factor Xa also limits the
production of proinflammatory cytokines as NF-κB is in-
activated [39]. Furthermore, heparan sulfates have been
shown to have numerous anti-inflammatory properties through
interactions with syndecan expressed on white blood cells [40].
Iba and Miyasho investigated the effect of danaparoid in an
intravenous lipopolysaccharide challenge model in rats [41].
The rats were divided into two groups and received either
danaparoid 400 U/kg or saline immediately after an intra-
venous lipopolysaccharide challenge. Blood samples were
taken at different time points for makers of organ injury,
coagulation markers and cytokines. Compared with saline-
treated rats, the rats receiving danaparoid presented less
evidence of organ injury, marginally better maintenance of
antithrombin and platelet levels, and significant suppression
of proinflammatory cytokine production [41]. The results of
this study were in keeping with those published by Hagiwara
and colleagues, where danaparoid improved survival in an
endotoxin-induced lung injury model and was associated with
decreased production of high mobility group box 1 (HMGB-1)
and proinflammatory cytokines [42]. It remains to be seen
whether danaparoid will be taken forward in clinical trials of
sepsis given the recent negative results of heparin in a severe
sepsis trial [43].
Immunoparalysis
While a majority of papers in the sepsis literature focus on an
exuberant proinflammatory and procoagulant response to
critical illness, it is clear that a state of immune suppression
or immunoparalysis also occurs in this setting. Lymphocyte
death by programmed cell death or apoptosis occurs in
critical illness patients via two pathways. The extrinsic
pathway is triggered by TNFα and Fas ligand – which bind to
death domains and ultimately activate caspase 8 and
caspase 3, leading to DNA fragmentation and cell death. The
intrinsic mitochondrial pathway is triggered by loss of growth
factors IL-2, IL-4 or granulocyte–macrophage colony-simu-
lating factor or by the addition of IL-6, IL-1, reactive oxygen
intermediates or nitric oxide. These signals can either activate
the proapoptotic BCL-2 family members Bax and t-Bid or the
anti-apoptotic BCL-2 and MCI-1 proteins [44].
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of the apoptotic kinetics in an animal model of hemorrhagic
shock. Mice who underwent bleeding to a mean arterial
pressure of 35 mmHg for 1 hour from the femoral artery
followed by fluid resuscitation were compared with sham
operated mice and control mice at 0 hours, 24 hours and
72 hours for lymphocyte counts, splenic lymphocyte apop-
tosis, caspase activity, and proapoptotic and antiapoptotic
protein levels. The authors found that lymphopenia occurs
very early in the mice undergoing hemorrhagic shock and that
it persists throughout the 72-hour observation period.
Furthermore, splenic apoptosis in hemorrhagic shock occurs
at 0 hours and 72 hours, and is associated with increased
activity of caspase 3/7, caspase 8 and caspase 9, and with
increased mitochondrial proapoptotic BAX levels and low
antiapoptotic Bcl-2 proteins. Interestingly, the antiapoptotic
protein MCI-1 is elevated at the 24 hours time point. These
data suggest a biphasic response to traumatic hemorrhage
where there is an attempt to counter-regulate proapoptotic
forces by antiapoptotic proteins that ultimately fails [45].
These findings support the notion that attempts to intervene
in trauma and sepsis by regulating the proapoptotic/
antiapoptotic balance might be a useful therapeutic strategy.
High mobility group box-1 polymorphisms and sepsis
HMGB-1 is a fascinating and markedly complex nuclear and
cytoplasmic protein that is readily measurable in the systemic
circulation in response to severe injury. The protein has the
propensity to bind to a variety of inflammatory mediators such as
lipopolysaccharide and proinflammatory cytokines, including IL-
1 [46]. HMGB-1 functions as an alarmin or damage-associated
molecular pattern molecule, and acts as an endogenous ligand
for pattern recognition receptors of the innate immune system.
In an important study on the outcome effects of polymor-
phisms of the HMGB-1 gene locus on human chromosome
13, Kornblit and colleagues reported the first evidence of the
HMGB-1 genotype’s impact on the risk of systemic
inflammatory response and sepsis [47]. These investigators
performed a long-term, 4-year study comparing HMGB-1
sequencing data in 239 ICU patients with HMGB-1 blood
levels and clinical outcomes. The authors report significant
disease associations with two of the eight major poly-
morphisms they discovered in the HMGB-1 gene complex. A
promoter variant (–1377delA) was associated with a
markedly reduced long-term survival rate after ICU admission
in systemic inflammatory response syndrome patients (15%
vs. 44% without this promoter variant; P <0.01). Kornblit and
colleagues also observed a significant interaction with a
polymorphism within the coding region of the HMGB-1 gene
at position 982 (C>T) in exon 4. Carriers of the polymorphism
had an increased frequency of early death from infection
along with higher Simplified Acute Physiology Score II
compared with wild-type genotypes. Interestingly, this
982C>T variant was accompanied by significantly lower
HMGB-1 blood levels (P <0.01).
Gene association studies need to be interpreted with caution,
and causality will remain elusive until larger datasets are
available in diverse patient populations of differing genetic
backgrounds. Linkage disequilibrium with other relevant gene
loci and attention to the Hardy–Weinberg equilibrium needs
to be carefully considered in small gene association studies.
Gene association reports in the ICU literature are improving
with respect to statistical methods and analytic detail but
have further room for improvement [48].
Conclusions
The pace of discovery in critical care research and allied
fields of inflammation research and infectious disease is truly
remarkable. Critical Care is helping the clinical investigator,
basic scientist, and clinician alike by reporting an array of
scientific papers in sepsis research. This trend is continuing
in 2009 and we are confident that exciting discoveries will
continue in this fast-paced area of critical care research.
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